

Leiomyosarcoma Therapeutic and Overview Pipeline Review H2

Leiomyosarcoma Treatment Pipeline Review H2 2016

PUNE, INDIA, November 11, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Leiomyosarcoma](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.



Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643484-leiomyosarcoma-pipeline-review-h2-2016> □

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
- The report reviews pipeline therapeutics for Leiomyosarcoma by companies and

universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Leiomyosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Leiomyosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Leiomyosarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Leiomyosarcoma - Overview 8

Pipeline Products for Leiomyosarcoma - Comparative Analysis 9

Leiomyosarcoma - Therapeutics under Development by Companies 10

Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 11

Leiomyosarcoma - Pipeline Products Glance 12

Late Stage Products	12
Clinical Stage Products	13
Leiomyosarcoma - Products under Development by Companies	14
Leiomyosarcoma - Products under Investigation by Universities/Institutes	15
Leiomyosarcoma - Companies Involved in Therapeutics Development	16
Advenchen Laboratories, LLC	16
BeiGene, Ltd.	17
Cell Medica Limited	18
Karyopharm Therapeutics, Inc.	19
Merck & Co., Inc.	20
Millennium Pharmaceuticals Inc	21
Mirati Therapeutics Inc.	22
Novartis AG	23
Pfizer Inc.	24
Vicore Pharma AB	25
Leiomyosarcoma - Therapeutics Assessment	26
Assessment by Monotherapy Products	26
Assessment by Target	27
Assessment by Mechanism of Action	29
Assessment by Route of Administration	31
Assessment by Molecule Type	33
Drug Profiles	35
AL-3818 - Drug Profile	35
Product Description	35
Mechanism Of Action	35
R&D Progress	35
axitinib - Drug Profile	38
Product Description	38
Mechanism Of Action	38
R&D Progress	38
BGB-290 - Drug Profile	44
Product Description	44
Mechanism Of Action	44
R&D Progress	44
C-21 - Drug Profile	46
Product Description	46
Mechanism Of Action	46
R&D Progress	46
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile	48
Product Description	48
Mechanism Of Action	48
R&D Progress	48

CMD-003 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
everolimus - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51

Access Report @ <https://www.wiseguyreports.com/reports/643484-leiomyosarcoma-pipeline-review-h2-2016> □

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts> □

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353456046>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.